Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For some real facts:
4-k filed 2/5/13
Specifically refer to Table 1, Items 4 & 5, for PROOF in rebuttal to the following:
For those who need HELP gathering real information on a real company with professional and experienced leaders fighting a real debilitating disease, go to the company website which has an abundance of quality, factual and verifiable information.
Amarantus Bioscience, Inc.
Management Team
Scientific Advisory Board
Board of Directors
Board of Advisors
For those who need HELP gathering real supporting documentation on a real company involved with other real companies in fighting a real debilitating disease, please visit the following websites (just to name a few):
Publication of Independent Peer-Reviewed Data
AMBS & Banyan Biomarkers TBI Collaboration
MJFF 2010 Grant Abstract
OneMedForum 2013 Video
IND Application Process
I know what I own and am YEARS LONG AMBS
PR from 11/20/12 - Amarantus BioSciences Wins MANF Patent Challenge in Europe
SUNNYVALE, Calif., Nov. 20, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced the Opposition Division of the European Patent Office upheld Amarantus Bioscience's European Patent relating to neurotrophic factor MANF, following opposition by rival Hermo Pharma OY of Finland.
The Opposition Division held that the Opponent's arguments did not prejudice the maintenance of the Patent as originally granted, with broad claims covering MANF and its derivatives. The Opponent had not contested the validity of the Patent on the basis of novelty or inventive step, but had objected to the broad scope of the claims. However, after due consideration of comprehensive legal and technical oral submissions from both sides, the Opposition Division rejected the Opponent's arguments and upheld the claims without restriction.
"This is a highly significant decision for Amarantus, after an extended period of uncertainty," said Marc Wilkinson PhD, European Patent Attorney of UK firm Avidity IP, representing Amarantus. "The Opposition Division's decision validates broad protection for MANF and derivatives across major European jurisdictions."
I know what I own and am YEARS LONG AMBS
AMBS' experienced management and advisory team are the consummate professionals. They are systematically leading a ground-breaking company in its quest to improve the quality of life for patients with PD (and other maladies) and shareholders.
I know what I own and am YEARS LONG AMBS
When it comes to investing my money, my DD takes into consideration the opinions of knowledgeable and experienced professionals in the field of interest. In re to AMBS and MANF (specifically), Dr. Joseph Rubinfeld, co-founder of Amgen, said it best:
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
I know what I own and am YEARS LONG AMBS
It is so nice to finally see some quality DD being done on the MJFF Grant process.
I'm very much looking forward to the upcoming MJFF Hot Topics Webinar to be held Tuesday, February 19th, at 12 PM EST and the subsequent anouncement of the next grant for continued MJFF-funded research that AMBS is sure to receive.
Keep up the good work all you intelligent LONGS.
I know what I own and am YEARS LONG AMBS
Dr. Joseph Rubinfeld, co-founder of Amgen, said it best:
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
It would seem he disagrees with:
I could not agree more! They HAD some outstanding financial issues they HAVE NOW resolved.
Stock Promoters
Type in BMSN then click GO.
AMBS is a VERY HIGH RETURN investment.
Nice another quality company about to change people's lives!!!
Another day of healthy, low volume consolidation. :)
This is overdue for a major run up.
Be careful sitting on the sidelines. You'll miss out.
Gerald is the consummate professional. Leading a ground-breaking company in improving the quality of life for intelligent shareholders and patients of PD.
Dr. Joseph Rubinfeld said it best:
It would seem he disagrees with:
I'm a glass half full kind of guy so I care to focus more on multi-billion $ company in the making.
I completely disagree with you.
My view is completely different. AMBS' potential brings out many intelligent people who invest in a company which is going to change lives. Real management, real science and real believers.
Manipulation and stupidity keeps putting more shares in the hands of intelligent and patient longs. Sort of like cutting off ones' nose to spite their face.
I know what I own and am years long AMBS
WARNING! Don't miss out on the next trip. Get on board AMBS if you want to make some real money based on real science and real management. Up 310% since 11/1/12.
I disagree with you.
Time relative information should not be OMITTED when trying to cite "facts."
To imply that hedge funds are universally bad is the same as saying all people have the same degree of education and intelligence.
Re AMBS, it seems the Michael J. Fox Foundation, Banyan Biomarkers and Dominion Capital LLC disagree with the following:
Amarantus BioSciences Wins MANF Patent Challenge in Europe
SUNNYVALE, Calif., Nov. 20, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced the Opposition Division of the European Patent Office upheld Amarantus Bioscience's European Patent relating to neurotrophic factor MANF, following opposition by rival Hermo Pharma OY of Finland.
The Opposition Division held that the Opponent's arguments did not prejudice the maintenance of the Patent as originally granted, with broad claims covering MANF and its derivatives. The Opponent had not contested the validity of the Patent on the basis of novelty or inventive step, but had objected to the broad scope of the claims. However, after due consideration of comprehensive legal and technical oral submissions from both sides, the Opposition Division rejected the Opponent's arguments and upheld the claims without restriction.
"This is a highly significant decision for Amarantus, after an extended period of uncertainty," said Marc Wilkinson PhD, European Patent Attorney of UK firm Avidity IP, representing Amarantus. "The Opposition Division's decision validates broad protection for MANF and derivatives across major European jurisdictions."
Dr. Joseph Rubinfeld
AMBS Corporate Advisor
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradeable detergent and polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
With all honesty, I do not think I could disagree with this more.
I believe the following is not true:
Average transaction today: 9729 shares and a whopping $815.
I'm thinking smart money is on the side.
Up 310 percent since 11/1/12! Glad I'm here for years and years. Life changing opportunity for those who know what they own.
According to the...
professional people and companies involved,
websites supporting the research and science,
intelligent articles written and
multitude of tther facts I've uncovered,
the following is absolutely not true.
My quality DD reveals the exact opposite.
Not true.
About 1% of the O/S actually traded yesterday.
Volume 4,944,000
Shorted 2,223,695
OTC Short Selling Report for AMBS
With the LONGS knowing what they own and having the float about locked up, the LONGS are not going to unload any significant quantity of shares until AMBS approaches a PPS based on its potential (and I would venture a guess that that is considerably north of the current PPS for many LONGS).
Absolutely agree that BETTER DD ALWAYS REVEALS FACTS FROM FICTION ABOUT AMBS!
AMBS and EVERY OTHER REAL BUSINESS IN AMERICA pay to promote their businesses and/or services. Whether advertising or promoting via newspapers, online, television, radio, phonebooks, etc., all companies pay to promote themselves.
I know what I own and am years long AMBS
Amarantus BioSciences Co-Founders honored among 2012's "50 Most Important African-Americans in Technology"
SUNNYVALE, Calif., Sept. 25, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a California-based biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented therapeutic protein MANF, today announced that Co-Founders Dr. John and Gerald Commissiong were selected among BlackMoney.com's 13th annual "50 Most Important African-Americans in Technology" for 2012. The selectees will gather in Washington, D.C. January 15th, 2013 for the Innovation & Equity Symposium: Keeping America First in Technology: Public Innovation and Supplier Diversity ( http://www.blackmoney.com/35117 ).
Dr. John W. Commissiong, Amarantus' Chief Scientific Officer, is the former Head of the Neurotrophic Factors Group at the National Institute of Neurological Disorders and Stroke (NINDS) who discovered and patented MANF. Gerald E. Commissiong, the Company's President & CEO, graduated from Stanford University's Management Science and Engineering program with a focus in Financial Decisions. Their bios can be viewed online at: http://www.amarantus.com/about-us/management-team.html .
Amarantus BioSciences Wins MANF Patent Challenge in Europe
SUNNYVALE, Calif., Nov. 20, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced the Opposition Division of the European Patent Office upheld Amarantus Bioscience's European Patent relating to neurotrophic factor MANF, following opposition by rival Hermo Pharma OY of Finland.
The Opposition Division held that the Opponent's arguments did not prejudice the maintenance of the Patent as originally granted, with broad claims covering MANF and its derivatives. The Opponent had not contested the validity of the Patent on the basis of novelty or inventive step, but had objected to the broad scope of the claims. However, after due consideration of comprehensive legal and technical oral submissions from both sides, the Opposition Division rejected the Opponent's arguments and upheld the claims without restriction.
"This is a highly significant decision for Amarantus, after an extended period of uncertainty," said Marc Wilkinson PhD, European Patent Attorney of UK firm Avidity IP, representing Amarantus. "The Opposition Division's decision validates broad protection for MANF and derivatives across major European jurisdictions."
Board of Advisors
Dr. Joseph Rubinfeld
Corporate Advisor
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradeable detergent and polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
For those who need HELP gathering real information on a real company with professional and experienced leaders fighting a real debilitating disease, go to the company website which has an abundance of quality, factual and verifiable information.
Amarantus Bioscience, Inc.
Management Team
Scientific Advisory Board
Board of Directors
Board of Advisors
For those who need HELP gathering real supporting documentation on a real company involved with other real companies in fighting a real debilitating disease, please visit the following websites (just to name a few):
MJFF Hot Topics Webinar of 2/19
MJFF AMBS 2010 Grant Abstract
AMBS & Banyan Biomarkers TBI Collaboration
I know what I own and am years long AMBS